Prestige Consumer Healthcare (PBH) Projected to Post Earnings on Thursday

Prestige Consumer Healthcare (NYSE:PBH) is anticipated to post its Q2 2026 results before the market opens on Thursday, November 6th. Analysts expect Prestige Consumer Healthcare to post earnings of $1.01 per share and revenue of $257.1380 million for the quarter. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS.Individuals may review the information on the company’s upcoming Q2 2026 earningreport for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.01 by ($0.06). The business had revenue of $249.53 million for the quarter, compared to analysts’ expectations of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The firm’s quarterly revenue was down 6.6% on a year-over-year basis. During the same period last year, the firm earned $0.90 earnings per share. On average, analysts expect Prestige Consumer Healthcare to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Prestige Consumer Healthcare Stock Up 0.0%

Shares of NYSE PBH opened at $60.58 on Wednesday. The company has a market capitalization of $2.98 billion, a price-to-earnings ratio of 14.22, a price-to-earnings-growth ratio of 1.93 and a beta of 0.44. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99. The business has a 50-day moving average of $63.41 and a two-hundred day moving average of $73.54. Prestige Consumer Healthcare has a 1 year low of $59.62 and a 1 year high of $90.04.

Analyst Ratings Changes

PBH has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, October 8th. Wall Street Zen cut Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Sidoti upgraded Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 target price on the stock in a research report on Wednesday, September 24th. Zacks Research cut Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Thursday, September 4th. Finally, Oppenheimer cut their target price on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 21st. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare has an average rating of “Hold” and a consensus target price of $87.33.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several institutional investors have recently added to or reduced their stakes in PBH. Geneos Wealth Management Inc. increased its position in Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after acquiring an additional 269 shares during the period. State of Wyoming acquired a new position in Prestige Consumer Healthcare in the 2nd quarter valued at about $97,000. Quantbot Technologies LP acquired a new position in Prestige Consumer Healthcare in the 2nd quarter valued at about $113,000. EverSource Wealth Advisors LLC increased its position in Prestige Consumer Healthcare by 151.6% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,454 shares of the company’s stock valued at $116,000 after acquiring an additional 876 shares during the period. Finally, Orion Porfolio Solutions LLC acquired a new position in Prestige Consumer Healthcare in the 2nd quarter valued at about $204,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.